Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUAPNF)

• Drug Name: humanin Drug Info
• Synonyms: formyl humanin

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Preclinical	[1]

• Cross-matching ID:
  PubChem CID: 16131438
  CAS Number: CAS 330936-69-1
  TTD Drug ID: DMUAPNF

Molecule-Related Drug Atlas

Drug(s) Targeting N-formyl peptide receptor 3 (FPR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LXA4	DMGSVL0	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting FMLP-related receptor I (FPR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[3H]resolvin D1	DMFT0HU	Discovery agent	N.A.	Investigative	[4]
LXA4	DMGSVL0	Discovery agent	N.A.	Investigative	[4]
PMID22607879CR-(-)-5f	DM7OJ5Q	Discovery agent	N.A.	Investigative	[5]
aspirin-triggered resolvin D1	DMOP941	Discovery agent	N.A.	Investigative	[6]
fMet-Leu-Phe	DMQ391A	N. A.	N. A.	Investigative	[7]
RvD1-ME	DM8EZTM	Discovery agent	N.A.	Investigative	[6]
pyrazolone, 1	DMLFQKU	Discovery agent	N.A.	Investigative	[8]
quin-C7	DM1CYWB	Discovery agent	N.A.	Investigative	[9]
aspirin triggered lipoxin A4	DMLBSNP	Discovery agent	N.A.	Investigative	[10]
quin-C1	DMVQYWS	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
FMLP-related receptor I (FPR2)	TTOJ1NF	FPR2_HUMAN	Agonist	[2]
N-formyl peptide receptor 3 (FPR3)	TT16TM5	FPR3_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT03431844) Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation. U.S. National Institutes of Health.
• [2] N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys Res Commun. 2004 Nov 5;324(1):255-61.
• [3] Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med. 1997 May 5;185(9):1693-704.
• [4] Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5.
• [5] Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem. 2012 Jun 15;20(12):3781-92.
• [6] Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27.
• [7] Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem. 1993 Aug 25;268(24):18167-75.
• [8] Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3713-8.
• [9] Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol. 2007 Oct;72(4):976-83.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 223).
• [11] A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol. 2004 Nov;66(5):1213-22.